Company / Capital Expenditures
Supernus Pharmaceuticals, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.3M
FY2025
5-year range
$412.0K / $1.3M
FY2021-FY2025
Trend
+84.6%
vs FY2024
Sector context
#107 of 194
Health Care
What the data says
At $1M, Supernus Pharmaceuticals, Inc.'s capital expenditures ranks #107 of 194 in the Health Care sector. Capital Expenditures has increased for 3 consecutive years, from $412,000 in FY2022 to $1M in FY2025.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -17.3%.
Improved from $551,000 to $1M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +48.1%
- 5-Year CAGR
- -17.3%
- 10-Year CAGR
- -
Sector benchmark
#107 of 194 in Health CareTop 55% of 194This company $1.3M Sector average $117.5M
▼
-98.9% below sector average
Key checks
Key Insights
- Supernus Pharmaceuticals, Inc.'s capital expenditures has grown for 3 consecutive years.
- 5-year CAGR of -17.3%, indicating a declining trend.
- In FY2025, capital expenditures increased 84.6% year-over-year.
- Ranks #107 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3M | +84.6% |
| FY2024 | $725.0K | +31.6% |
| FY2023 | $551.0K | +33.7% |
| FY2022 | $412.0K | - |
| FY2021 | - | - |
| FY2020 | $3.4M | +26.1% |
| FY2019 | $2.7M | +70.7% |
| FY2018 | $1.6M | -23.8% |
| FY2017 | $2.1M | +254.8% |
| FY2016 | $593.0K | -71.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026